Twice Daily Dosing with the Highly Specific BTK Inhibitor, Bgb-3111, Achieves Complete and Continuous BTK Occupancy in Lymph Nodes, and Is Associated with Durable Responses in Patients (pts) with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Constantine S. Tam(The Alfred Hospital), Andrew W. Roberts(The Royal Melbourne Hospital), Jianxin Yang(BeiGene (China)), Sumita Ratnasingam(Monash Health), Eric Hedrick(Florida Hospital Cancer Institute), David Simpson(North Shore Hospital), Paula Marlton(The University of Queensland), Mark Kirschbaum(Cyclacel Pharmaceuticals (United States)), David Ritchie(Peter MacCallum Cancer Centre), Matthew Ku(St Vincent's Hospital Melbourne), John F. Seymour(The Royal Melbourne Hospital), Judith Trotman(The University of Sydney), Stephen Opat(Monash Health), Mary Ann Anderson(The Royal Melbourne Hospital), Ling Xue(Jilin University), Bradley Augustson(National Health Service), Gavin Cull(Sir Charles Gairdner Hospital), Lai Wang(BeiGene (China)), David Gottlieb(The University of Sydney)
Cited by 37
Related Papers
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k